Primarily known as an immunology and neuroscience company, AbbVie wanted to put the biopharma world on notice during its J.P.

AstraZeneca is relying on several upcoming products to help hit its target of $80 billion in revenue by 2030, including drugs ...

A more detailed review of data by the FDA showed that GLP-1 drugs do not increase the risk of suicidal ideation or behavior.

At a J.P. Morgan media event Tuesday, the Gilead C-suite seemed to be walking on air as they highlighted Yeztugo’s capture of ...

Three years after the accelerated approval of its anti-amyloid Alzheimer’s therapy, Biogen—neck and neck in the market with ...

After a period of diversification, Novo Nordisk is returning to its roots by focusing on the 2 billion people with diabetes, ...

An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation ...

Biopharma companies—including AstraZeneca, BioNTech and Agios—peered farther into the future on the second day of JPM, ...

Buying vaccine biotech Dynavax was an easy choice for Sanofi despite antivaccine moves by the Trump administration.

AbbVie and Novartis strike billion-dollar pacts while attendees at the J.P. Morgan Healthcare Conference await that one big M ...

CEO and cofounder of Earli, a Silicon Valley-based cancer therapeutics firm that creates genetic switches that only turn on ...

Obesity took center stage on the first day of the 2026 J.P. Morgan Healthcare Conference, with industry frontrunners Eli ...